tuneTypical Dose
About 10-40 g/day (type and tolerance dependent)
Fiber Supplement
Resistant Starch
Resistant starch (RS1-RS4)
Evidence TierBWADA NOT PROHIBITED
watchEffect Window
Usually weeks to a few months.
check_circleCompliance
WADA NOT PROHIBITED
Overview
Clinical Summary
Resistant starch is a fermentable fiber that increases short-chain fatty acid production.
Resistant starch can improve selected glycemic and inflammatory markers, especially in insulin-resistant or higher-risk cohorts, but the response is inconsistent across starch type, dose, and baseline microbiome profile. A 2025 placebo-controlled MASLD trial adds modern support for liver-fat improvement while also showing that roughly one-third of users may respond poorly when baseline microbiota are unfavorable.
Fermentable non-digestible starch supports SCFA-mediated gut-metabolic pathways and can improve selected glycemic and inflammatory endpoints.
Outcomes
What This Is Expected To Influence
Primary Outcomes
- Improved selected glycemic outcomes in prediabetes/T2D
- Beneficial metabolic-risk marker trends
Secondary Outcomes
- Inflammation/oxidative marker improvements
- Possible CKD-supportive biomarker effects
Safety
Contraindications and Interactions
Contraindications
- Severe active GI flare states
- Intolerance to fermentable fibers
- Inability to maintain hydration
Side effects
- Bloating/gas
- Abdominal discomfort
- Stool-pattern changes
Interactions
- Minimal direct drug interactions
- Possible medication-timing interference with high fiber intake
- Additive GI burden with stacked fermentable fibers
Avoid if
- Severe uncontrolled IBS/SIBO without guidance
- Rapid dose-escalation behavior
- No objective monitoring plan
Evidence
Study-level References
resistant-starch-SRC-001Systematic review and meta-analysis.
Sourceopen_in_newWang N, et al. A comparison of the effects of resistant starch types on glycemic response in individuals with type 2 diabetes or prediabetes: A systematic review and meta-analysis. Front Nutr. 2023;10:1118229. doi:10.3389/fnut.2023.1118229. PMID:37051127.
Population: Prediabetes/T2D intervention trials.
Dose protocol: RS type-stratified interventions.
Key findings: Type-dependent glycemic improvements.
Notes: Heterogeneity by RS type and protocol.
Paper content
Type-dependent glycemic improvements.
resistant-starch-SRC-002Systematic review and meta-analysis.
Sourceopen_in_newGomez-Arango LF, et al. Effects of resistant starch consumption on anthropometric and serum parameters in adults with metabolic syndrome-related risks: a systematic review and meta-analysis. Front Nutr. 2025;12:1655664. doi:10.3389/fnut.2025.1655664. PMID:41080169.
Population: 23 RCTs in adults with metabolic-risk profiles.
Dose protocol: Parallel/crossover RS interventions.
Key findings: Beneficial effects on selected anthropometric/serum outcomes.
Notes: Broad heterogeneity in intervention conditions.
Paper content
Beneficial effects on selected anthropometric/serum outcomes.
resistant-starch-SRC-003Systematic review and meta-analysis.
Sourceopen_in_newZhang Y, et al. The Effects of Resistant Starch on Biomarkers of Inflammation and Oxidative Stress: A Systematic Review and Meta-Analysis. Nutr Cancer. 2022;74(9):3118-3131. doi:10.1080/01635581.2021.2019284. PMID:35188032.
Population: 16 RCTs, 739 participants.
Dose protocol: RS interventions lasting 2 weeks to 3 months.
Key findings: Decrease in selected inflammatory/oxidative markers.
Notes: Mixed populations and interventions.
Paper content
Decrease in selected inflammatory/oxidative markers.
resistant-starch-SRC-004Systematic review and meta-analysis.
Sourceopen_in_newWang Y, et al. Effects of Resistant Starch on Patients with Chronic Kidney Disease: A Systematic Review and Meta-Analysis. Biomed Res Int. 2022;2022:1861009. doi:10.1155/2022/1861009. PMID:35899018.
Population: CKD clinical trials.
Dose protocol: RS supplementation versus controls.
Key findings: Favorable trends in some renal/inflammatory outcomes.
Notes: Limited number/size of CKD trials.
Paper content
Favorable trends in some renal/inflammatory outcomes.
resistant-starch-SRC-005Randomized placebo-controlled trial with mechanistic microbiome analysis
Sourceopen_in_newLong X, et al. Interindividual variability in gut microbiome mediates the efficacy of resistant starch on MASLD. Cell Metab. 2025;37(12):2342-2361.e9. doi:10.1016/j.cmet.2025.10.017. PMID:41270737.
Population: Adults with metabolic dysfunction-associated steatotic liver disease
Dose protocol: Randomized, placebo-controlled resistant starch trial in MASLD with response stratification by baseline microbiome.
Key findings: Resistant starch improved MASLD-related outcomes overall, but about 30% of participants had limited benefit and response depended strongly on baseline microbiota.
Notes: Important repair to the old assumption that resistant starch works uniformly across users.
Paper content
Resistant starch improved MASLD outcomes overall, but efficacy varied widely across individuals. Baseline microbiota strongly influenced response, with Prevotella-associated profiles linked to poor response and targeted microbiome support potentially restoring benefit.
resistant-starch-SRC-006Randomized controlled trial with multi-omics analysis.
Sourceopen_in_newPetrov VA, Schade S, Laczny CC, et al. Resistant starch improves Parkinson's disease symptoms through restructuring of the gut microbiome and modulating inflammation. Brain Behav Immun. 2026;125:106217. doi:10.1016/j.bbi.2025.106217. PMID:41389850.
Population: Adults with Parkinson's disease.
Dose protocol: Resistant starch supplementation in 74 Parkinson's disease patients with multi-omics analysis.
Key findings: Resistant starch increased Faecalibacterium and SCFAs, reduced opportunistic pathogens, increased blood APOA4 and HSPA5, and reduced PD symptoms.
Notes: Novel gut-brain axis evidence extending resistant starch benefits into a neurodegenerative population.
Paper content
This RCT tested resistant starch supplementation in 74 Parkinson's disease patients using multi-omics analysis. Resistant starch increased Faecalibacterium and short-chain fatty acid production while reducing opportunistic pathogens. Long-term supplementation also increased blood APOA4 and HSPA5 and reduced PD symptoms. The trial provides novel evidence that resistant starch can modulate the gut-brain axis in a neurodegenerative population, extending the known metabolic and inflammatory benefits into a neurological context.
resistant-starch-SRC-007Randomized, double-blind pilot study.
Sourceopen_in_newKim et al. Effects of resistant starch on metabolic markers and gut microbiota in women with metabolic syndrome risk factors: a randomized, double-blind, pilot study. Nutrients. 2025;17(23):3652. doi:10.3390/nu17233652. PMID:41373942.
Population: Women with metabolic syndrome risk factors.
Dose protocol: High versus low resistant starch diet in 30 women with metabolic risk factors for 8 weeks.
Key findings: Blood pressure improved modestly, but triglycerides increased approximately 40 mg/dL in the high-RS group. Body weight and body fat also increased.
Notes: Cautionary pilot study showing that resistant starch responses are not uniformly beneficial for lipid outcomes.
Paper content
This double-blind pilot RCT tested high versus low resistant starch diets in 30 women with metabolic risk factors over 8 weeks. While blood pressure improved modestly, the high-RS group showed concerning increases in body weight, body fat, and triglycerides. Microbiota shifted with increased Veillonella in the high-RS group. The authors concluded that dietary resistant starch interventions should incorporate regular lipid monitoring. This trial adds an important cautionary signal to the resistant starch literature, showing that metabolic responses are not uniformly beneficial.